The FDA warns that both CJC-1295 and ipamorelin carry risks of immunogenicity (triggering immune responses) and cardiovascular effects, including "increased heart rate and systemic vasodilatory reaction." One clinical trial of CJC-1295 was discontinued following a participants death, though the attending physician believed the event was "unrelated to treatment." Neither CJC-1295 nor ipamorelin is FDA-approved
This portable energy drink ensures you stay fueled and ready for action
Zhang HY, Yang GH, Chen HJ, Wei B, Ke Q, Guo H, Ye L, Bu H, Yang K, Zhang YH

Inside the GLP-1 Boom: What a Biotech Analyst and PhD/Nutritionist Thinks Mini-deep dive on the fastest growing healthcare opportunity from an investment and health perspective This is for: Science enthusiasts Pharma/biotech consultants, analysts Investors in the life science space Doctors, nutritionists, health coaches, fitness coaches People considering or already on weight loss medication Longevity enthusiasts I help you: Understand what weight loss medications are Get a list of the key obesity players in the pharma/biotech space Understand lifestyle strategies to get the best outcomes out of GLP1s Free Resources included: Obesity development landscape and launch timelines Weight loss data from key drugs in development Comment Health and I will share a US market model template to help you forecast weight loss drug sales yourself See inside for disclosure Intro to Weight Loss Medications (WLMs) Unless you are living under a rock, the words GLP1, Ozempic, Wegovy, Mounjaro, weight-loss medication must not be new to you
